登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
ClinicalTrials.gov 上登记的一项胃癌开放试验,由河南省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07334431,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;
入选标准第 3 条
Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
排除标准第 3 条
Poorly controlled diabetes mellitus was present before enrollment (fasting glucose concentration ≥CTCAE level 2 after formal treatment);
排除标准第 14 条
Unmitigated toxicity higher than CTCAE v5.0 grade 1 due to any previous anticancer therapy, excluding alopecia, lymphocytopenia, and oxaliplatin grade ≤2 neurotoxicity;
排除标准第 20 条
Received blood transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF), within 14 days before enrollment;
排除标准第 22 条
Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
入选标准第 6 条
Absolute neutrophil count ≥1.5×109/L;
入选标准第 10 条
Platelet ≥100×109 /L;
入选标准第 11 条
Hemoglobin ≥90g/L;
入选标准第 12 条
Total bilirubin < 1.5 ULN;
入选标准第 13 条
ALT and/or AST < 1.5 ULN ;
入选标准第 14 条
Serum creatinine (Cr) <1.5×ULN;
入选标准第 15 条
Endogenous creatinine clearance ≥50ml/min;
入选标准第 16 条
International Standardized Ratio (INR) >1.5 or partially activated prothrombin time (APTT) >1.5×ULN;
排除标准第 11 条
At least one measurable lesion according to RECIST version 1.1;
入选标准第 8 条
Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
排除标准第 21 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07334431,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Have fully understood the study and voluntarily signed the informed consent; 18-75 years old (including 18 and 75 years old); Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma; No previous anti-tumor treatment for metastatic diseases; HER2 positive; Eastern Cooperation Oncology Group (ECOG) performance status of 0-1; Life expectancy ≥ 3 months; At least one measurable lesion according to RECIST version 1.1; The functions of vital organs met the following requirements (Blood components and cell growth factors were not allowed within 14 days before enrollment): Absolute neutrophil count ≥1.5×109/L; Platelet ≥100×109 /L; Hemoglobin ≥90g/L; Total bilirubin < 1.5 ULN; ALT and/or AST < 1.5 ULN ; Serum creatinine (Cr) <1.5×ULN; Endogenous creatinine clearance ≥50ml/min; Female patients of childbearing age should take effective contraceptive measures; Good compliance, cooperate with follow-up.排除标准:Exclusion Criteria:
Failure to comply with the study protocol or study procedure; Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, chemotherapy or immune checkpoint inhibitors; Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix; Known presence of symptomatic central nervous system metastasis or brain metastases; Had autoimmune disease or history of autoimmune disease within 4 weeks before enrollment; Previously received allogeneic bone marrow transplantation or organ transplantation; Uncontrolled malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture as determined by the researcher); Severe cardiovascular disease, including unstable angina pectoris or myocardial infarction, occurs within 6 months before the start of study treatment; Subjects who are allergic to the investigational drug or any of its adjuncts; Participated in other domestic unapproved or unmarketed drug clinical trials and accepted the corresponding experimental drug treatment within 4 weeks before enrollment; International Standardized Ratio (INR) >1.5 or partially activated prothrombin time (APTT) >1.5×ULN; The investigator identified clinically significant electrolyte abnormalities; Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg; Poorly controlled diabetes mellitus was present before enrollment (fasting glucose concentration ≥CTCAE level 2 after formal treatment); Had any disease or condition prior to enrollment that affected drug absorption, or the patient could not take fruquintinib orally; Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unresectosed tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by researchers before enrollment; Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months >30 mL, hematemesis, stool, stool blood), hemoptysis (within 4 weeks >5 mL of fresh blood) or had a thromboembolic event (including stroke events and/or transient ischemic attacks) within 12 months; Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) <50%; Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) >50%; Unmitigated toxicity higher than CTCAE v5.0 grade 1 due to any previous anticancer therapy, excluding alopecia, lymphocytopenia, and oxaliplatin grade ≤2 neurotoxicity; Women who are pregnant (positive pregnancy test before medication) or breastfeeding; Received blood transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF), within 14 days before enrollment; Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, reasonably suspects that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or which would affect the interpretation of the study results or place the patient at high risk; Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein volume > 1.0g; Complications require long-term treatment with immunosuppressants or systemic or local use of immunosuppressive corticosteroids (> 10mg/ day prednisone or other therapeutic hormone); Investigators believe that the patient has any other conditions that are not suitable for participating in the study.
引自 ClinicalTrials.gov, NCT07334431, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07334431,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。